Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

Core Insights - Senti Biosciences reported initial positive results from its Phase 1 clinical trial of SENTI-202 for treating relapsed/refractory acute myeloid leukemia (AML), with two out of three patients achieving complete remission and being measurable residual disease (MRD) negative [1][4] - The company raised approximately $47.6 million through private investment in public equity (PIPE) financing, which is expected to extend its financial runway into 2026 [5] - Senti Bio received a total of$6.4 million from the California Institute for Regenerative Medicine (CIRM) grant to support the clinical development of SENTI-202 [6] Pipeline and Corporate Highlights - SENTI-202 is being developed for relapsed/refractory hematologic malignancies, including AML, with initial data indicating a well-tolerated treatment profile [3][4] - The company has expanded its leadership team, appointing Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations [7] - Fran Schulz and Feng Hsiung were appointed to the Board of Directors, bringing extensive experience in finance and investment [8] Financial Results - As of December 31, 2024, Senti Bio held cash and cash equivalents of $48.3 million, a significant increase from$35.9 million in 2023 [12][15] - Research and development expenses for Q4 2024 were $7.8 million, down from$9.1 million in Q4 2023, while general and administrative expenses also decreased to $8.4 million from$9.3 million [12][17] - The net loss for Q4 2024 was $0.6 million, or$0.67 per share, compared to a net loss of $18.7 million, or$4.19 per share, in Q4 2023 [12][18]